Nyxoah SA

NYXH Healthcare Medical Devices

Nyxoah SA’s revenue for fiscal 2025 (year ended December 2025) was $11.3 million, up 131.7% from fiscal 2024.

Revenue
+486.6%
EPS
−6.35%
Free cash flow
+4.01%
Total debt
+185.4%

Quarter to June 2026, against a year earlier

0.85 0.04 +4.94%
Market cap
$82.6M
P/E
0.0×
Fwd P/E
−0.8×
Dividend yield
—
F-score
3/9
Altman Z
−4.39
Beneish M
−2.78
Dividend safety
n/a

Nyxoah SA (NYXH) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Nyxoah SA (NYXH) trades at a EV/Sales of 0.1×. Over the past ten years it has ranged from 0.0× (March 2022) to 258× (March 2022); the current reading is higher than 17% of that period. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 14.8× (62.44%)
FY2024 39.4× 124.34%
FY2023 17.6× 17.85%
FY2022 14.9× —
FY2021 0.0× —
FY2020 0.0× —

Quarterly newest first

Period EV/Sales Change
Jun 2026 2.1× (73.42%)
Mar 2026 7.8× (47.50%)
Dec 2025 14.8× (46.43%)
Sep 2025 27.6× (41.84%)
17 more quarters

Against its own ten years

Low 0.0× High 258×
Ten-year median 29.9×
Current reading's percentile 0

EV/Sales against peers

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on NYXH